FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burd	len
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Weintraub Bennett</u>						2. Issuer Name and Ticker or Trading Symbol Apimeds Pharmaceuticals US, Inc. [APUS]									ationship of Reporting Person(s) to Issuer k all applicable) Director 10% Owner					
(Last) (First) (Middle) 2 EAST BROAD STREET						3. Date of Earliest Transaction (Month/Day/Year) 05/16/2025									Office below	r (give title)		Other (s	specify	
2ND FLOOR (Street) HOPEWELL NJ 08425						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (CheckApplicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																	
1. Title of Security (Instr. 3) 2. Tran Date				2. Trans Date	cative Securities Accarding 2A Deemed Execution Date, if any (Month/Day/Year				3. Transacti Code (Ins	on .	4. Secu	of, or Be rities Acqu ed Of (D) (I	ired (A) or	A) or 5. A 3, 4 Sec Ber Ow		Amount of ecurities eneficially wned ollowing		n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount (A) or (D)		Price		Reported Transaction(s) (Instr. 3 and 4)					
		Ta	able II -						uired, Dis s, options					y O	wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A Deemed Execution Date, if any (Month/Day/Year)		4. Transactic Code (Instr. 8)		on Number I		6. Date Exer Expiration I (Month/Day/	ate	Amount of		f s ng	of Dei Sec	Price rivative curity str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ownershi Form: Iy Direct (D) or Indirect (I) (Instr.		Beneficia Ownersh	
						v	(A)	(D)	Date Exercisable	Ex Da	piration te	Title	Amount or Number of Shares							
Stock Option (right to buy)	\$1.73	05/16/2025			A		5,780		(1)	05/	/16/2035	Common Stock, par value \$0.01 per share	5,780		\$0	5,780		D		

Explanation of Responses:

1. The option will vest in full and become exercisable on 05/16/2026.

/s/ Nelson Mullins Riley &

Scarborough LLP, Attorney-in- 05/20/2025

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).